Academic Institutes

Provided below is a representative list of public institutions that conduct research using human embryonic stem (ES) cells.


Berkeley Stem Cell Center The Center's scientific efforts include the differentiation of stem cells into blood, nerve and muscle cells, and the effects of aging or engineered extracellular environments on these processes.

Center for iPS Cell Research and Application /Kyoto University Led by Dr. Shinya Yamanaka, CiRA is focused on the mechanisms that underlie the reprogramming process, differentiation and transplantation of iPSCs, and generation of iPSCs with genetic mutations.

Harvard Stem Cell Institute The HSCI research program is focused on basic research and clinical translation using human ES cells for treatment of diabetes, nervous system diseases, blood diseases and cardiovascular diseases.

Sloan-Kettering Institute Human and Murine Embryonic Stem Cell Program has been developing conditions for inducing the differentiation of H1 human ES cell line into hematopoietic lineage, lymphoid lineage and endothelial lineage.

Stanford Institute for Stem Cell Biology and Regenerative Medicine Researchers are studying the development of human ES cells during early tissue formation to test their use in tissue regeneration. The institute is also committed to creating new human ES cell lines using nuclear transfer for studying genetic diseases.

UC Davis Stem Cell Program Research efforts include identification of novel molecules that cause self renewal, use of ES cells for transplantation and tissue repair in cardiovascular disease.

UCSF Institute for Regeneration Medicine Research is aimed at gaining a better understanding of how defined types of tissues develop, and is directed toward cell-based approaches to the treatment of diseases of the hematopoietic, musculoskeletal, neural, cardiovascular and reproductive systems.

University of Minnesota: Stem Cell Institute Research emphasis is currently on human ES cells that can become hematopoietic cells and endothelial cells.

University of Wisconsin/Embryonic Stem Cell Research Research focus areas include basic stem cell biology, neural and heart regeneration, blood stem cells and pancreatic islet cell replacement.



Australian Stem Cell Centre Research has focused on the creation of new cell lines, new markers to identify these cells in the body and methods to characterize, differentiate and propagate these cells.

Centre for Stem Cell Biology (UK) Research is focused on production of new cell lines, characterization and neural differentiation of human ES cells.

EuroStemCell Consortium comprised of eleven academic institutes and enterprises from eight European countries. Research aims to derive new cell lines, control self-renewal and differentiation processes in order to achieve neurological, muscular and epidermal repair using cell therapies.

Hadassah Human Embryonic Stem Cell Research Center (Israel) Research activities include derivation of new stem cell lines, production of pure differentiated cell populations for transplantation in diabetes and Parkinson’s disease, and development of genetically modified human ES cells for gene therapy.

Institute for Stem Cell Research (UK) Studies focus on signaling pathways that direct stem cell self-renewal and differentiation

Institute of Human Genetics at the University of Newcastle upon Tyne Research activities include molecular characterization of hES cells, and their differentiation into pancreatic, haematopoietic and germ cell lineages.

Kyoto University (Japan) The Stem Cell Research Center’s aims are to establish and characterize new human ES cell lines, control stem cell differentiation, and engineer functional tissues from stem cells.

RIKEN Center for Developmental Biology (Japan) The laboratory for Stem Cell Biology is developing culture conditions for guided differentiation of ES cells.

Stem Cell Research Singapore Research interests include derivation and propagation of xeno-free human ES cell lines for cell based therapies and in vitro pharmaceutical testing, and mechanisms controlling human ES cell renewal, pluripotency and differentiation.

University of Cambridge (UK) Studies at the Wellcome Trust Centre for Stem Cell Research aim to characterise and understand the regulatory processes and machinery that govern self-renewal and lineage programming.


Stem Cell Companies

The following is a sampling of the companies developing human embryonic stem (ES) cell lines.


Advanced Cell Technology – Los Angeles, CA, Alameda, CA, Worcester, MA – ACT’s human ES programs involve generation of retinal pigment epithelium cells for treatment of eye diseases and hemangioblasts for treatment of heart disease, stroke and cancer. Programs also investigate new methods for generation of human ES cell lines.

Geron - Menlo Park, CA - Their human ES cell programs are developing differentiated human ES cell based therapies for spinal cord injury, Parkinson's disease, heart disease, diabetes, osteoblasts for osteoporosis, osteoarthritis, and blood diseases. Geron owns nine human ES cell lines.

Novocell – San Diego, CA, Athens, GA – Merged with Bresagen and Cythera. Human ES programs involve directed differentiation of human ES cells into specific therapeutic cell types such as insulin producing cells for the treatment of diabetes. Novocell owns three human ES cell lines available for NIH funded research.


Cellartis AB – Göteborg, Sweden, Dundee, UK – Uses human ES cells for drug discovery, toxicity testing and regenerative medicine with the main objective to develop hepatocytes and cardiomyocytes from these cells. Cellartis has developed over 30 human ES lines, two of which are listed in the NIH Registry.

ES Cell International – Singapore – Development of differentiated human ES cells as replacement therapies for heart disease and diabetes. ESI also develops new human ES cell lines, owning six lines currently available for NIH funded research in the US.

Reliance Life Sciences – Navi Mumbai, India – ES cell programs involve the derivation and characterization of human ES cell lines and their differentiation into specific lineages for cell based therapies and toxicological screening for numerous diseases.

Roslin Cells – Roslin, Scotland (UK) – A not-for-profit company established by the Roslin Institute to create and market clinically useable human ES cell lines.


Our collaborators:

Stembook Link